Niranjan Y. Sardesai, PhD
Founder, President & CEO
Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer. He held positions of increasing responsibility after joining the company in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine … Read more
Joann Peters, MHA
Chief Operating Officer
Joann Peters joined Geneos after a successful 19-year career working in the Contract Research Organization (CRO) industry where she supported the growth strategy of companies and effectively led oncology focused study teams. She is bringing her strong oncology clinical operations experience to Geneos and will play a pivotal role in the company’s growth by leading the … Read more
Federica O’Brien
Consulting Chief Financial Officer
Presently Freddi is President of CFO’Brien Consulting, LLC, for which she provides executive level strategic and financial consulting services. Freddi has previously held the roles of Chief Financial Officer, Chief Operating Officer, Controller and Director of Financial Reporting and has been integral in the growth and financing of both private and public companies ranging from … Read more
Jian Yan, PhD
Vice President, Research and Discovery
Dr. Yan joined Geneos to lead the research team and brings with her over 15 years of experience in leading preclinical research programs for the development of novel immunotherapies. Prior to joining Geneos, she served as the Vice President of Design and Product Development at NEUVOGEN, where she was responsible for design and development of … Read more
Ildiko Csiki, MD, PhD
Consulting Chief Medical Officer
Dr. Csiki most recently served as the chief commercial research and development (R&D) officer at City of Hope, an NCI-designated leading cancer center, where she led the development of a translational biotech-like R&D arm and oversaw the research business development and the office of transfer and licensing functions. Previously, Dr. Csiki served as the … Read more
Shawn Tomasello, MBA
Advisor
Shawn Cline Tomasello joined Kite Pharma in 2015 as Chief Commercial Officer (CCO) with over 30 years of experience in pharmaceutical and biotech industries. She was a key executive in the Kite/Gilead acquisition for $11.9 Billion in August 2017. Prior to joining Kite Pharma, Ms. Tomasello was the CCO of Commercial and Medical Affairs at … Read more
Chi Van Dang, MD, PhD
Scientific Director, Ludwig Institute for Cancer Research; Bloomberg Distinguished Professor of Cancer Medicine, Johns Hopkins University
Dr. Chi Van Dang is scientific director of the Ludwig Institute for Cancer Research and Bloomberg Distinguished Professor of Cancer Medicine at Johns Hopkins University. He is also Professor of Oncology, Cell Biology, and Biochemistry and Molecular Biology at Johns Hopkins. Dang’s research helped define the complex functions of the MYC oncogene, a central switch … Read more
David B. Weiner, PhD
Chair Scientific Advisory Board; W.W. Smith Endowed Chair in Cancer Research, The Wistar Institute
Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, … Read more
Samuel Broder, MD
Former Director of the National Cancer Institute
Samuel Broder is the former head of the National Cancer Institute (NCI), the largest and most important Agency for cancer research in the world. President Ronald Reagan appointed Dr. Broder to serve as Director of the NCI in 1989, and he held the position for six years. While at the NCI, he also oversaw the … Read more
Casey Cunningham, MD
Chief Scientific Officer, Santé Ventures
Casey Cunningham, MD is the Chief Scientific Officer of Santé Ventures. Dr. Cunningham received his fellowship training in oncology and hematology at the Harvard Medical School, where he subsequently served on the faculty for a number of years. In 1999, he became the Associate Director of the Mary Crowley Cancer Research Institute in Dallas, Tx. … Read more